Results 1 to 10 of about 447,577 (315)
Oncology and Therapy, 2023 This podcast, for healthcare professionals (HCPs), patients, and patient advocates, is a discussion among a panel of two patients (and co-founders of the patient advocacy group EGFR Resisters, https://egfrcancer.org/ ) and two oncologists.
Stephen V. Liu +3 more
doaj +1 more source
Frontiers in Bioscience-Landmark, 2023 Background: The aim of the current study was to investigate the anticancer potential of bioactive compounds isolated from the leaves of Olea ferruginea (O. ferruginea). Lignans from O.
Abdur Rauf +11 more
doaj +1 more source
Journal of Dr. NTR University of Health Sciences, 2023 Background: In this study, we assessed the immunohistochemical expression of EGFR and Ki-67 in cases of oral squamous cell carcinoma and its association with grading and staging.
Sayali Gadre +5 more
doaj +1 more source
The Uncertainty of the eGFR [PDF]
Indian Journal of Clinical Biochemistry, 2012 The estimated glomerular filtration rate (eGFR) is a parameter derived from the serum creatinine, patient age and gender and is used to ascertain renal function. It is subject to variation because of the analytical error of the creatinine measurement and biological variation.
Badrick, Tony, Turner, Peter
openaire +2 more sources
Cell, 2012 The epidermal growth factor receptor (EGFR) is normally activated by ligand-induced dimerization. Oncogenic mutations in EGFR promote activation in a largely ligand-independent manner. Shan et al. uncover a partially disordered state of EGFR kinase, providing evidence that oncogenic mutations counteract this intrinsic structural instability to promote ...
Eck, Michael J., Hahn, William C.
openaire +2 more sources
Cancer Discovery, 2012 Abstract Erlotinib and gefitinib inhibit the growth of non–small cell lung cancer tumors that harbor activating epidermal growth factor receptor (EGFR) mutations but are ineffective against EGFR variants found in glioblastoma. New studies by Barkovich and colleagues and Vivanco and colleagues show that these drugs only occupy the active ...
Jin H, Park, Mark A, Lemmon
openaire +2 more sources
Midazolam impedes lung carcinoma cell proliferation and migration via EGFR/MEK/ERK signaling pathway
Open Medicine, 2023 Non-small-cell lung cancer (NSCLC) is a dominating type of lung cancer with high morbidity and mortality. Midazolam has been reported to promote cell apoptosis in NSCLC, but the molecular mechanism of midazolam remains to be further explored.
Zhang Xiangchao +3 more
doaj +1 more source
Journal of Biochemical and Clinical Genetics, 2021 Background: C-terminal tensin-like (CTEN) is a protein located at focal adhesions and has been reported to be an oncogene in the colon, breast, lung, and gastric cancer.
Saleh AlGhamdi +4 more
doaj +1 more source
A CRISPR Test for Rapidly and Sensitively Detecting Circulating EGFR Mutations
Diagnostics, 2020 The detection of EGFR mutations in circulating cell-free DNA can enable personalized therapy for cancer. The current techniques for detecting circulating EGFR mutations are expensive and time-consuming with moderate sensitivity.
Jen-Hui Tsou, Qixin Leng, Feng Jiang
doaj +1 more source
Water-soluble pristine C60 fullerene attenuates acetaminophen-induced liver injury [PDF]
BioImpacts, 2019 Introduction: Oxidative stress has been suggested as the main trigger and pathological mechanism of toxic liver injury. Effects of powerful free radical scavenger С60 fullerene on rat liver injury and liver cells (HepG2 line) were aimed to be discovered.
Halyna Kuznietsova +6 more
doaj +1 more source